zary cells can be classified as reactive or neoplastic based on the presence or absence of detection of clonal TCR-P rearrangements by Southern blot analysis. We evaluated two unequivocal disease groups: individuals with definitive clinical and/or histologic diagnoses of benign inflammatory dermatoses, and individuals with the clinicopathologic diagnosis of SS who had circulating Sezary cells in the peripheral blood and clonal TCR-P gene rearrangements in the skin.
MATERIALS AND METHODS
Patient selection and sample triage. Twenty-five individuals were analyzed in this study: 11 with benign inflammatory dermatoses (six cases of psoriasis, three cases of atopic dermatitis, two cases of erythrodermic drug reactions), 11 patients with SS, and three normal controls. All cases of benign inflammatory dermatoses (BID) had been previously categorized on clinical and/or histologic criteria. Patients with SS were receiving extracorporeal photopheresis, with or without systemic interferon-alpha," and all had histories of prior skin-directed therapies (topical mechlorethamine, phototherapy, or electron beam therapy). BID patients (atopic dermatitiddrug reaction) were being treated with topical or systemic corticosteroids. Psoriatic patients were being treated with phototherapy and/or systemic retinoids; some had histories of prior methotrexate therapy. After informed consent was given, blood was obtained via venipuncture from each patient, and portions of each sample were used for the following purposes: a complete blood cell count, a Sezary cell count, and peripheral blood lymphocyte isolation and genomic DNA extraction.'n In addition, from patients with SS, punch biopsies of
skin were obtained, from which genomic DNA was extracted.I7 Sezay counts. Anticoagulated blood samples were centrifuged, and the white cell buffy coat was fixed in glutaraldehyde. After sectioning and dehydration, buffy coat sections were embedded in each patient was calculated as the product of the Sezary count, the white blood cell count, and the percent lymphocytes recorded on the complete blood cell count differential.
Southern blot andpolvmerase chain reaction (PCR) ana1vsi.r. Peripheral blood mononuclear cells were purified from patients' periphg.j era1 blood by Ficoll Hypaque sedimentation gradient centrifugation, snap-frozen in liquid nitrogen, and stored at -80°C. High-molecularweight DNA was extracted from samples as previously described." DNA (7.5 pg) was digested to completion using two to five different restriction endonucleases (HindlIl, Xha I, EcoRI, EcoRV, BamHI). Electrophoresis (0.7% agarose gel), membrane transfer, prehybridization, hybridization, washing, and autoradiography were performed as previously described.'" A probe to the constant region of the TCR-B (CB) geneI7 was labeled by nick translation'n using cr-"P deoxycytidine triphosphate (dCTP). For one patient in the study, PCR amplification of peripheral blood lymphocyte genomic DNA was performed using TCR-Vy and TCR-Jy consensus oligonucleotide primers, and the amplification products were analyzed by denaturing gradient gel electrophoresis (DGGE), similar to the method of Wood et al." of mononuclear cells, and the Sezary counts of the patients with S S ranged from 12% to 78%. The results of TCR-P gene rearrangement studies by Southern blot analysis from patients with BID and S S and normal controls are summarized in Table 1 . All 11 patients with S S demonstrated a TCR-P gene rearrangement on Southern blot analysis of skin. Figure 2 shows Southern blot analysis representative of two groups of S S : one demonstrating identical rearrangements in skin and blood (8 of 1 l), and the other demonstrating rearrangement only in the skin (3 of 1 l). The three patients that did not demonstrate a clonal TCR-P gene rearrangement on Southern blot analysis of the peripheral blood had Sezary counts ranging from 14% to 52% (Table l) , which should be well within the detection sensitivity of Southern blot analysis.'
One of 11 patients with BID demonstrated a TCR-P gene rearrangement in the peripheral blood by Southern blot analysis. The patient had biopsy-proven plaque-type psoriasis (patient BID-l, Table 1 ) and a Sezary count of 2% on initial would demonstrate a CP2 rearrangement (Fig 3) . These findings suggested the presence of a relatively small population of monclonal or oligoclonal T cells." When reexamined 9 months later, Southern blot analysis demonstrated the same result. However, the patient's Sezary count was 0%. For confirmation, PCR/DGGE analysis of peripheral blood lymphocyte genomic DNA was also performed on this patient. At two different time points, the patient demonstrated a detectable monoclonal TCR--y gene rearrangement (Fig 4) . regardless of the presence or absence of detectable circulating Sezary cells. The patient shows no evidence of progression to cutaneous or systemic malignancy 2 years after his initial evaluation by Southern blot analysis. The 10 other patients with BID and the three normal control patients did not demonstrate detectable rearrangements in the peripheral blood by Southern blot analysis. be heterogeneous. In 3 of the 1 1 patients with S S that we studied, circulating Sezary cells were interpreted as polyclonal or reactive based on their lack of a detectable TCR-0 gene rearrangement by Southern blot analysis. These patients with S S had Sezary counts between 14% and 52%; therefore. our failure to detect rearrangements in these patients was not secondary to detection sensitivity." Our findings corroborate and extend previous genotypic studies of CTCL that demonstrate the absence of TCR gene rearrangements in the presence of circulating Sezary cells.'".'3-"' These findings, along with morphologic, cytogenetic,I3 and immunophenotypic studies,'.'' clearly demonstrate that polyclonal circulating Sezary cells may differ from the monoclonal malignant T cells infiltrating the skin and, therefore, may be termed reactive rather than neoplastic. lanes l and 3) and Vyl-8 and Jyl-2 (lanes 2 and 4) . An ethidium bromide-stained gel reveals the identical clonal bands (arrowheads) detected with V+ and Jyl-2 at both time points (lanes 1 and 3) . Negative controls (peripheral blood lymphocytes from healthy young adults) are in lanes 5 and 6, and a positive control (Jurkat T-cell lymphoma cell line) is in lane 7.
WEINBERG ET AL with an unequivocal diagnosis of plaque-type psoriasis with no other underlying disease-a TCR-0 gene rearrangement was detected. Repeat Southern blot analysis with multiple restriction enzyme digestions ensured that the rearranged bands were not artifactual (eg, partial digestion or plasmid contamination) and provided a means to identify the specific TCR-/3 locus (Col or Cp2) involved in the rearrangement. Our results (Fig 3) demonstrate rearrangement involving the Col locus, which can represent the presence of either a monoclonal or oligoclonal population of T cells." However, TCR-y PCWDGGE analysis demonstrated a monoclonal gene rearrangement (Fig 4) . These molecular findings were present both with and without detectable circulating Sezary cells. making the Sezary cells an unlikely source of the TCR gene rearrangements.
We speculate that our unexpected finding of a monoclonal TCR gene rearrangement in the peripheral blood of a psoriatic patient may reflect the role of the host immune response to pathogenic antigens or superantigens that may play an etiologic role in psoriasis.2x h u n g et alZx studied two patients with acute exacerbations of psoriasis that appeared to be triggered by bacterial infection. Using monoclonal antibodies, they showed that skin biopsies from each patient demonstrated a restricted pattern of TCR-VD that corresponded to the Vp pattern expected to be induced by the type of superantigen expressed during the infection. Using PCR and sequence analysis, Chang et al'" demonstrated that CD8' T cells in psoriatic lesions preferentially use TCR V83 and/or V013.1 genes. The clonality of the V, sequence data suggested clonal expansion in situ in response to an antigen or antigens in the skin. Clonal dominance, or selective expansion of one (monoclonal) or more (oligoclonal) pathogenic T-cell clones with similar TCR-P gene rearrangements, has been well documented in nonmalignant clinical disorders such as allograft rejection," autoimmune diseases,'" and large granular Posnett et al" have also described clonal CD8' T-cell populations in the blood of normal donors aged over 65 years. They speculated that these clones may represent cytoFor personal use only. on August 16, 2017. by guest www.bloodjournal.org From toxic T cells with specificity for ubiquitous viruses or that they may be autoreactive cells, the T-cell equivalent of benign clonal gammopathies. The findings in our patient, at age 73 years, may be consistent with their observations. In 5 of 10 normal human individuals studied, Hingorani et noted the clonal predominance of T-cell receptors within the CD8+CD45RO+ subset. They hypothesized that these cells may represent antigen-specific effector cells or populations of regulatory T cells.
One of the most important issues raised by our findings and those of other^",^',^^ is the proper interpretation of a TCR rearrangement in the peripheral blood in a benign or unknown setting. As noted above, monoclonality is not an exclusive feature of malignancy and can be seen in benign or reactive settings3' Bakels et a135 analyzed the peripheral blood of 19 patients with benign exfoliative erythrodermas. One of these 19 patients (with the diagnosis of chronic dermatitis) demonstrated a clonal TCR-/3 gene rearrangement in the peripheral blood. No correlation with Sezary counts was provided. Wood et a12' reported evidence of dominant T-cell clonality by PCR/DGGE of skin samples in 6 of 105 non-CTCL/SS cases studied. These six cases consisted of four cases of nonspecific dermatitis and two cases of cutaneous lymphoid hyperplasia. They concluded that it will be important to determine the long-term risk of CTCWSS among these patients with chronic clonal dermatitis and recommended close follow up. The question, therefore, is whether the presence of TCR clonal rearrangements in benign settings indicates the existence or potential risk of malignancy or, perhaps, reflects an as yet undefined mechanism.
